ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    M

    Dr Martin Dietrich,

    Medical professional dedicated to sharing knowledge and insights through educational videos.

    Dr. Martin Dietrich reviews the evidence trastuzumab deruxtecan (T-Dxd) in gastric cancer (Video 2/3)

    Dr. Martin Dietrich reviews the evidence trastuzumab deruxtecan (T-Dxd) in gastric cancer (Video 2/3)

    T-Dxd in Gastric

    Martin Dietrich
    GI Cancers
    Dr. Martin Dietrich discusses the efficacy of trastuzumab deruxtecan (T-Dxd) in HER2+ colorectal cancer (Video 1/3)

    Dr. Martin Dietrich discusses the efficacy of trastuzumab deruxtecan (T-Dxd) in HER2+ colorectal cancer (Video 1/3)

    T-Dxd in HER2+ CRC

    Martin Dietrich
    GI Cancers
    Implementation strategies for amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    Implementation strategies for amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    MARIPOSA-2 Implementation

    Dr. Martin Dietrich
    Lung Cancer
    Safety of amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    Safety of amivantamab+chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    MARIPOSA-2 Safety

    Dr. Martin Dietrich
    Lung Cancer
    Efficacy of Amivantamab + chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    Efficacy of Amivantamab + chemotherapy in patients with mNSCLC that have progressed on osimertinib (MARIPOSA-2)

    MARIPOSA-2 Efficacy

    Dr. Martin Dietrich
    Lung Cancer